Please login to the form below

Not currently logged in
Email:
Password:

India revokes Pfizer's patent on Sutent

Loses patent protection for kidney cancer drug after Cipla and Natco challenge

Pfizer has become the latest Western drugmaker to fall foul of India's increasingly contentious intellectual property (IP) environment, losing patent protection for its kidney cancer drug Sutent.

The country's Patent Office revoked the basic patent for Sutent (sunitinib malate) on the grounds that it did not include an inventive step, backing the position taken up by Indian drugmakers Cipla and Natco Pharma in a legal challenge to Pfizer's IP.

Cipla had argued that the inventiveness of Pfizer's patent was compromised by "structural obviousness", in other words the compound's structure could have been deduced from similar drugs already covered by earlier patents.

Pfizer said immediately it would lodge an appeal against the Patent Office's decision, which is the third defeat for a major pharma company in India in as many weeks, all involving widely-used cancer drugs.

The company sells its Sutent product for 1.96 lakh (about $3,800) for a 45-day course, and Cipla says it will make its Sunitib version available at a 10 per cent discount, according to a LiveMint report.

Last month, Bayer failed in a bid to overturn a compulsory license which removed patent protection for its Nexavar (sorafenib) cancer drug, allowing a cut-price competitor from Natco to enter the market. 

Just a few days before the Nexavar verdict Roche lost a four-year legal dispute with Cipla over patent rights to Tarceva (erlotinib), while Novartis is still in the throes of a long-running legal dispute as it tries to defend blockbuster cancer drug Glivec (imatinib) and is expecting a verdict before the end of this year.

Pfizer had already protected Sutent from a compulsory license challenge in 2008, a year after the company was awarded its patent and launched the product, and in an interview with the Business Standard said the Patent Office's latest action "raised concerns over India's commitment to protect intellectual property".

5th October 2012

From: PME

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Anthill_icon_Green_02_Digital.png
How to get your sales force to use digital tools
You have the perfect digital strategy. You provide the most advanced digital sales tools. You power it with amazing content. And then discover that customer-facing staff aren’t using it. Wait....
Highlights: Ashfield leads by example, engaging attendees at Pharma Forum
During this year’s Pharma Forum, held at the Gaylord National Convention Center in National Harbor, Maryland, David Kerr (Senior Director of Creative & Production Services) co-hosted an insightful session surrounding...
How to find pharma content that inspires your audience
Getting your customers’ attention begins with presenting pharma content that speaks to their needs and wants effectively....

Infographics